TRIACET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIACET (TRIACET).
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
| Metabolism | Triacetin is hydrolyzed by esterases in the skin and systemically to glycerol and acetic acid. The acetic acid is further metabolized via the tricarboxylic acid cycle. |
| Excretion | Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment. |
| Protein binding | Approximately 40% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.2–0.3 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is 60–80% (mean ~70%); presence of food may reduce absorption. |
| Onset of Action | Oral: Clinical effects begin within 1–2 hours following administration. |
| Duration of Action | Clinical effects persist for 4–6 hours after an oral dose; duration may be extended with sustained-release formulations. |
| Molecular Weight | 434.5 |
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (GFR ≥30 mL/min). For severe renal impairment (GFR <30 mL/min), reduce dose by 50% or extend dosing interval. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Avoid use or reduce dose by 75%. |
| Pediatric use | Children >1 month: 0.1-0.5 mg/kg/day orally divided every 8 hours; maximum 2 mg/kg/day. |
| Geriatric use | Initiate at low end of dosing range (0.5 mg three times daily); titrate cautiously due to increased risk of hypotension and arrhythmias. |
| 1st trimester | Triacet (triamcinolone acetonide) is a corticosteroid. Use in first trimester only if benefit outweighs risk; associated with oral clefts in animal studies. |
| 2nd trimester | Use in second trimester with caution; risk of intrauterine growth restriction with prolonged use. |
| 3rd trimester | Use in third trimester may cause neonatal adrenal suppression; avoid prolonged use. |
Clinical note
Comprehensive clinical and safety monograph for TRIACET (TRIACET).
| Placental transfer | Triamcinolone acetonide crosses the placenta; fetal blood levels about 40% of maternal levels. |
| Breastfeeding | Triamcinolone acetonide is excreted in human milk in low amounts. No adverse effects reported in infants, but caution with high doses or prolonged use. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to triamcinolone or any componentSystemic fungal infection
| Precautions | For external use only., Avoid contact with eyes, mouth, and mucous membranes., Discontinue use if irritation or sensitization occurs., Not for use on nails or scalp unless specifically indicated., Use in pregnancy only if clearly needed. |
| Food/Dietary | None known; no specific dietary restrictions. However, if using oral triamcinolone, avoid grapefruit juice as it may increase drug levels. For topical and ophthalmic forms, no food interactions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L2 (Safer) |
| Teratogenic Risk | Triacet is a combination of acetaminophen and codeine. Codeine crosses the placenta and may cause respiratory depression in the neonate if used near term. Chronic use during pregnancy may lead to neonatal withdrawal syndrome. First trimester: possible association with neural tube defects (controversial, limited data). Second trimester: no clear major malformation risk. Third trimester: risk of respiratory depression, withdrawal; prolonged use may cause neonatal opioid withdrawal syndrome. |
| Fetal Monitoring | Monitor maternal pain relief, respiratory rate, and signs of opioid toxicity. Fetal monitoring: nonstress test and biophysical profile in third trimester if chronic use. Neonatal monitoring: observe for respiratory depression, sedation, withdrawal (e.g., irritability, poor feeding) for 48 hours after delivery. |
| Fertility Effects | No direct evidence of fertility impairment from acetaminophen. Codeine may cause hormonal alterations (e.g., increased prolactin) that could affect ovulation in women; in men, chronic opioid use may lead to hypogonadism and reduced fertility. |
| Triacet (triamcinolone acetonide) is a corticosteroid used for inflammatory conditions. Intralesional injection can cause skin atrophy; avoid injecting into infected or ulcerated lesions. For ophthalmic use, monitor intraocular pressure, especially with prolonged therapy. Do not use in patients with active tuberculosis or fungal infections. |
| Patient Advice | Do not use Triacet for longer than prescribed or on large areas of skin without consulting your doctor. · Avoid applying to broken or infected skin; report any signs of infection or worsening symptoms. · Wash hands before and after application unless treating hands. · Do not use with occlusive dressings unless directed by your doctor. · For ophthalmic use, do not wear contact lenses during treatment and report any vision changes or eye pain immediately. |